ClinicalTrials.Veeva

Menu

Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer (ADC)

C

Centre Jean Perrin

Status

Withdrawn

Conditions

Assess the Variation of Apparent Diffusion Coefficient

Treatments

Other: MRI (Magnetic resonance imaging)

Study type

Interventional

Funder types

Other

Identifiers

NCT01956513
Etude ADC

Details and patient eligibility

About

The main objective of the study is to assess the sensitivity and the specificity of the variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant chemotherapy or after modification of the treatment sequence, the pathological response at the end of chemotherapy

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age> 18 years.
  • Patient suffering from a breast tumor, regardless of the stage and size
  • Patient requiring neoadjuvant chemotherapy
  • Patient has the ability to undergo 18F-FDG-PET at baseline, at end of cycle 1 and at the end of neoadjuvant treatment before surgery
  • Compulsory affiliation to a social security system.
  • Obtaining informed consent in writing, signed and dated.

Exclusion criteria

  • Patient with cognitive or psychiatric disorders.
  • Patient deprived of liberty by a court or administrative.
  • Patient with signs against the achievement of MRI, mammography and ultrasound
  • Patient metastatic
  • Patient with prior chemotherapy, radiotherapy and hormone therapy for her breast cancer
  • Pregnant women, current lactation
  • Patient suffering from uncontrolled diabetes (> 11 mmol / L)

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems